Abstract
Radiation therapy is a widely used treatment for locally advanced non-small cell lung cancer, as well as for a variety of other thoracic malignancies. Radiation induced lung injury (RILI) refers to any lung-related change resulting from this treatment. From a clinical standpoint, RILI is separated into two distinct syndromes: an acute pneumonitis beginning 2-10 weeks following RT and a more indolent fibrotic process, presenting months after initial exposure. A variety of factors have been identified that are associated with an increased risk of developing clinically significant RILI. These include treatment-related factors (dose and schedule of radiation, volume of lung irradiated, concurrent use of chemotherapy) and patient-related factors (age, gender, smoking status, presence of pre-existing lung disease). New insights into the mechanisms of radiation induced lung injury have been uncovered, and these findings have led to the development of novel strategies for the prevention and treatment of this complication. In this review, we will discuss the clinical manifestations and risk factors of RILI, and focus on recent advances in its pathogenesis and treatment.
Keywords: Radiation pneumonitis, radiotherapy, lung cancer
Current Respiratory Medicine Reviews
Title: Radiation-Induced Lung Injury Following Therapy for Thoracic Malignancy
Volume: 1 Issue: 3
Author(s): Ross K. Morgan, Lisa A. Kachnic and Ross Summer
Affiliation:
Keywords: Radiation pneumonitis, radiotherapy, lung cancer
Abstract: Radiation therapy is a widely used treatment for locally advanced non-small cell lung cancer, as well as for a variety of other thoracic malignancies. Radiation induced lung injury (RILI) refers to any lung-related change resulting from this treatment. From a clinical standpoint, RILI is separated into two distinct syndromes: an acute pneumonitis beginning 2-10 weeks following RT and a more indolent fibrotic process, presenting months after initial exposure. A variety of factors have been identified that are associated with an increased risk of developing clinically significant RILI. These include treatment-related factors (dose and schedule of radiation, volume of lung irradiated, concurrent use of chemotherapy) and patient-related factors (age, gender, smoking status, presence of pre-existing lung disease). New insights into the mechanisms of radiation induced lung injury have been uncovered, and these findings have led to the development of novel strategies for the prevention and treatment of this complication. In this review, we will discuss the clinical manifestations and risk factors of RILI, and focus on recent advances in its pathogenesis and treatment.
Export Options
About this article
Cite this article as:
Morgan K. Ross, Kachnic A. Lisa and Summer Ross, Radiation-Induced Lung Injury Following Therapy for Thoracic Malignancy, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774597992
DOI https://dx.doi.org/10.2174/157339805774597992 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Biological Evaluation of Cyanopyridines, Pyridopyrazolopyrimidines and Pyridopyrazolotriazines as Potential Anticancer Agents
Current Organic Synthesis The IGF Axis in Prostate Cancer
Current Pharmaceutical Design Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry Understanding Apoptosis in Terms of QSAR
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry Recent Synthesis of Marine Natural Products with Antibacterial Activities
Anti-Infective Agents in Medicinal Chemistry Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism Precursors of Magnetic Resonance Imaging Contrast Agents Based on Cystine-coated Iron-oxide Nanoparticles
Current Physical Chemistry Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Medicinal Chemistry Distamycin A as Stem of DNA Minor Groove Alkylating Agents
Current Topics in Medicinal Chemistry Molecular Mechanisms Responsible for <i>In Vitro</i> Cytotoxic Attributes of <i>Conyza bonariensis</i> Extract against Lymphoblastic Leukaemia Jurkat Cells
Anti-Cancer Agents in Medicinal Chemistry Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design